|
Market Report
|
Cystic Fibrosis - A pipeline full of hope
With cystic fibrosis patients still dying prematurely and only two products currently approved for the treatment of this disease, the market is wide open for new entrants. Not only will novel symptomatic treatments and re-formulations lead to improved treatment paradigms, truly disease-modifying compounds are in late-stage development and will significantly change the market.
|
|
Read more...
|
|
|
Market Report
|
Bone building drugs become the heart of the pipeline
Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6.9 billion in 2009. Nonetheless, several promising pipeline drugs will help the market resume growth.
|
|
Read more...
|
|
|
Market Report
|
Market players maximize revenue growth before the next challenging phase
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005/09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.
|
|
Read more...
|
|
|
Market Report
|
|
Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market
Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drugs. The NGF class has potential to be first of an entirely new type of painkiller to enter the sector in decades. Nevertheless, high expectations need to be tempered once the long term side effects, safety and pharmacoeconomics have been established.
|
|
Read more...
|
|
|
Market Report
|
Fibromyalgia - Regulatory caution threatens EU market expansion
Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market for all current and future brands indicated for fibromyalgia. Datamonitor forecasts the fibromyalgia market to more than double in value from 2008 to total $2.5 billion by 2018 across the seven major regions.
|
|
Read more...
|
|
|
Market Report
|
Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease
Incidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate cancer, two-thirds of which are novel targeted therapies or immunotherapies. Collectively, the nine drugs in late-phase development are forecast to achieve $2,780m in sales by 2018.
|
|
Read more...
|
|
|
Market Report
|
Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
No therapeutic cancer vaccine has received approval in any of the seven major pharmaceutical markets, despite extensive research efforts. However, with one product in pre-registration in the US, the prospect of the first marketed therapeutic cancer vaccine in the seven major markets is now closer to reality.
|
|
Read more...
|
|
|
Market Report
|
Hepatitis C - High unmet need drives rapid innovation
The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.
|
|
Read more...
|
|
|
Market Report
|
Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey
China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 19 - 27 of 366 |
Farmavita.Net Journal 
